biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ALLO. Primary therapeutic focus areas include Relapsed/Refractory Large B Cell Lymphoma, Relapsed/
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
Quick answer
Allogene Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ALLO. Primary therapeutic focus areas include Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Multiple Myeloma, Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Systemic Lupus Erythematosus (With and Without Nephritis), Large B-cell Lymphoma. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 16 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (4), phase 2 (4).
Company snapshot
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning
- 8 active pipeline program(s) linked via ClinicalTrials.gov.
- 16 US patent(s) indexed to this assignee profile.
- 8 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Allogene Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Allogene CEO David Chang Steps Down: Implications for the Biotech Sector
Recent coverage
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Phase 2
- Phase 2
Active clinical programs
- Phase 2
- Phase 2
- Phase 2
- Phase 2
Momentum
Proprietary activity score for Allogene Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Allogene Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Allogene Therapeutics?
-
Is Allogene Therapeutics publicly traded?
-
What drugs does Allogene Therapeutics develop or market?
-
What are the latest developments for Allogene Therapeutics?
-
What therapeutic areas does Allogene Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.